Examkin

Soru

Zorluk: OrtaRheumatology and Immunology

A 32-year-old woman with a history of systemic lupus erythematosus presents to the clinic with new-onset bilateral lower extremity edema, worsening fatigue, and newly elevated blood pressure of 150/95 mmHg. Recent laboratory studies show worsening normocytic anemia, hypocomplementemia (decreased C3 and C4), and an increasing serum creatinine level from 0.8 mg/dL to 1.6 mg/dL. Arrange the following clinical steps in the most appropriate sequential order for the standard diagnosis and management of this patient's suspected complication.

  1. 1Perform urinalysis with microscopy and quantify proteinuria (e.g., spot urine protein-to-creatinine ratio).
  2. 2Perform a percutaneous ultrasound-guided renal biopsy to establish the histologic class.
  3. 3Initiate induction therapy with a potent immunosuppressive agent (e.g., mycophenolate mofetil) and high-dose glucocorticoids.
  4. 4Transition to long-term maintenance immunosuppressive therapy with lower-dose glucocorticoids.

Cevap

The correct sequence begins with non-invasive confirmation using urinalysis and protein quantification, followed by a renal biopsy for histologic classification, then intensive induction immunosuppression, and finally transitioning to long-term maintenance therapy.
Lupus nephritis is a major organ-threatening complication of systemic lupus erythematosus. The standard of care demands a stepwise approach: initially confirming the presence of renal injury with non-invasive tests (urinalysis, spot protein-to-creatinine ratio), followed by an invasive renal biopsy to precisely classify the histologic severity (Classes I-VI). Because treatments for severe proliferative classes (III and IV) involve highly toxic agents, biopsy confirmation is mandatory before exposing the patient to these risks. Once confirmed, induction therapy (high-dose steroids plus an agent like mycophenolate or cyclophosphamide) is started to rapidly induce remission. After 3 to 6 months of successful induction, therapy is de-escalated to a maintenance regimen (e.g., lower-dose mycophenolate or azathioprine) to sustain remission while reducing long-term adverse effects.

Adım Adım Çözüm

1
Confirm and quantify renal involvement non-invasively.
Urinalysis and urine protein-to-creatinine ratio demonstrate active urine sediment and significant proteinuria.
Before performing invasive procedures, clinical suspicion of lupus nephritis must be corroborated by non-invasive functional markers of renal injury.
2
Obtain tissue for histologic classification via renal biopsy.
Biopsy results classify the disease severity (e.g., Class IV diffuse proliferative lupus nephritis).
Because treatment regimens range from observation to highly toxic immunosuppressants, tissue diagnosis is required to guide appropriate therapy without exposing patients to unnecessary risks.
3
Administer induction immunosuppressive therapy.
Active renal inflammation is halted, and renal function begins to stabilize or improve.
Severe classes of lupus nephritis require immediate, aggressive treatment (e.g., mycophenolate mofetil or cyclophosphamide with high-dose steroids) to prevent permanent end-stage renal disease.
4
De-escalate to maintenance immunosuppressive therapy.
The patient maintains disease remission on a less toxic medication regimen.
Prolonged use of induction agents carries high risks of toxicity (e.g., infection, malignancy, infertility); thus, transitioning to a safer maintenance regimen is necessary once initial remission is achieved.

Anahtar Kavram

Diagnosis and step-wise management of lupus nephritis
Bu soruyu puanla

Konular

Rheumatology and Immunology

Bu konudan daha fazla soru